Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

Who May Qualify: 1. Diagnosis of neovascular glaucoma 2. The patients having IOP \> 21 mmHg, having the indication for trabeculectomy 3. The patients' age of at least 18-year-old 4. The patients having visual potential at least hand motion. 5. Present of NVI or NVA. 6. Willing and able to provide willing to sign a consent form to participate in the study 7. Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits Who Should NOT Join This Trial: 1. One eye patient 2. Patients having severe corneal edema or total hyphema obscure NVI or NVA view. 3. Cannot obtain endothelial cell count. 4. History of bevacizumab or fluorescence dye allergy. 5. Active infectious ocular disease including endophthalmitis and corneal ulcer 6. History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension 7. Has or planning to be pregnant or breastfeeding Always talk to your doctor about whether this trial is right for you.